Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Oliver Gerhard, Ottmann"'
Autor:
Claudia Chiriches, Nathalie Nicolaisen, Maria Wieske, Heba Elhaddad, Ecmel Mehmetbeyoglu, Caroline Alvares, Dörte Becher, Paul Hole, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 18, Iss 10, p e1010463 (2022)
The WHO classifies t(6;9)-positive acute myeloid leukemia (AML) as a subgroup of high-risk AML because of its clinical and biological peculiarities, such as young age and therapy resistance. t(6;9) encodes the DEK/NUP214 fusion oncoprotein that targe
Externí odkaz:
https://doaj.org/article/b9784da331f645fe9b92d4e7d5409c3f
Autor:
Afsar Ali Mian, Usva Zafar, Syed Muhammad Areeb Ahmed, Oliver Gerhard Ottmann, El-Nasir M A Lalani
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 1016-1027 (2021)
Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and ponatinib have significantly improved the life expectancy of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) patients; however, resistance to TKIs r
Externí odkaz:
https://doaj.org/article/c89ed034f8fc4dd9a60bfeb6318d1115
Autor:
Claudia Chiriches, Dilawar Khan, Maria Wieske, Nathalie Guillen, Michal Rokicki, Carol Guy, Marieangela Wilson, Kate J. Heesom, Oliver Gerhard Ottmann, Martin Ruthardt
Patients within the WHO-subgroup of t(6;9)-positive acute myeloid leukemia (AML) differ from other AML subgroups as they are characterised by younger age and a grim prognosis. Leukemic transformation can often be attributed to single chromosomal aber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c32fa14515f5be58a1c40634745b85
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
Autor:
Anahita Rafiei, Afsar Ali Mian, Claudia Döring, Anna Metodieva, Claudia Oancea, Frederic B Thalheimer, Martin Leo Hansmann, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 11, Iss 4, p e1005144 (2015)
The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia. The t(9;22) is a recipro
Externí odkaz:
https://doaj.org/article/e656123223284eafa41f1d7b430b3911
Autor:
Afsar Ali, Mian, Isabella, Haberbosch, Hazem, Khamaisie, Abed, Agbarya, Larissa, Pietsch, Elizabeh, Eshel, Dally, Najib, Claudia, Chiriches, Oliver Gerhard, Ottmann, Oliver, Hantschel, Ricardo M, Biondi, Martin, Ruthardt, Jamal, Mahajna
Publikováno v:
Annals of Hematology
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c713ae1181071ce445731d4bcbdc0f4
https://pubmed.ncbi.nlm.nih.gov/34110462
https://pubmed.ncbi.nlm.nih.gov/34110462